% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Hamid:283200,
      author       = {R. Hamid and M. Alaziz and A. S. Mahal and A. W. Ashton and
                      N. Halama$^*$ and D. Jaeger$^*$ and X. Jiao and R. G.
                      Pestell},
      title        = {{T}he {R}ole and {T}herapeutic {T}argeting of {CCR}5 in
                      {B}reast {C}ancer.},
      journal      = {Cells},
      volume       = {12},
      number       = {18},
      issn         = {2073-4409},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DKFZ-2023-01965},
      pages        = {2237},
      year         = {2023},
      abstract     = {The G-protein-coupled receptor C-C chemokine receptor 5
                      (CCR5) functions as a co-receptor for the entry of HIV into
                      immune cells. CCR5 binds promiscuously to a diverse array of
                      ligands initiating cell signaling that includes guided
                      migration. Although well known to be expressed on immune
                      cells, recent studies have shown the induction of CCR5 on
                      the surface of breast cancer epithelial cells. The function
                      of CCR5 on breast cancer epithelial cells includes the
                      induction of aberrant cell survival signaling and tropism
                      towards chemo attractants. As CCR5 is not expressed on
                      normal epithelium, the receptor provides a potential useful
                      target for therapy. Inhibitors of CCR5 (CCR5i), either small
                      molecules (maraviroc, vicriviroc) or humanized monoclonal
                      antibodies (leronlimab) have shown anti-tumor and
                      anti-metastatic properties in preclinical studies. In early
                      clinical studies, reviewed herein, CCR5i have shown
                      promising results and evidence for effects on both the tumor
                      and the anti-tumor immune response. Current clinical studies
                      have therefore included combination therapy approaches with
                      checkpoint inhibitors.},
      subtyp        = {Review Article},
      keywords     = {CCR5 (Other) / breast cancer (Other) / triple-negative
                      breast cancer (Other)},
      cin          = {D240 / D120},
      ddc          = {570},
      cid          = {I:(DE-He78)D240-20160331 / I:(DE-He78)D120-20160331},
      pnm          = {314 - Immunologie und Krebs (POF4-314)},
      pid          = {G:(DE-HGF)POF4-314},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37759462},
      doi          = {10.3390/cells12182237},
      url          = {https://inrepo02.dkfz.de/record/283200},
}